Waystar Holding (WAY) Valuation After Earnings Beat And AI Platform Momentum

Waystar Holding stock reacts to earnings beat and AI platform momentum

Waystar Holding (WAY) has been in focus after reporting first quarter 2026 revenue and earnings that exceeded consensus expectations. The company reaffirmed full year revenue guidance and highlighted traction in its AI powered revenue cycle management platform.

See our latest analysis for Waystar Holding.

Despite the post earnings bounce, with a 1 day share price return of 2.68% and 7 day share price return of 1.74%, the stock is still under pressure. The 90 day share price return is down 25.09% and the 1 year total shareholder return is down 49.94%, suggesting recent optimism around the AI platform and guidance has yet to reverse a broader loss of confidence.

If strong AI execution is on your radar, it can be useful to see how other companies in the space are trading and growing through our screener of 39 healthcare AI stocks

With revenue and net income both growing at double digit rates and the stock trading at a discount to some intrinsic estimates and analyst targets, you have to ask: is Waystar undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 41.9% Undervalued

Waystar Holding’s most widely followed narrative points to a fair value of $34.26 per share versus the last close at $19.91, framing a sizeable valuation gap for investors to assess.

The acquisition of Iodine Software, a leading provider of AI-powered clinical intelligence, will expand Waystar’s total addressable market by over 15%, accelerate its product roadmap, and immediately boost gross margins and adjusted EBITDA margins, setting up compounding, long-term revenue and earnings growth.

Read the complete narrative.

Curious what justifies that higher fair value? The narrative focuses on steady revenue expansion, rising profit margins, and a richer future earnings multiple than today.

Result: Fair Value of $34.26 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this upside story can crack if the US$1.25b Iodine acquisition does not deliver expected synergies, or if larger health systems push through tougher pricing.

Find out about the key risks to this Waystar Holding narrative.

Another View: What The Earnings Multiple Is Telling You

The first narrative leans on discounted cash flows and a fair value of $34.26, yet the current P/E of 30.3x screens as a mixed signal. It sits below peers on 42.8x, above the global industry on 27.4x, and slightly richer than a 27.6x fair ratio, which hints at both upside and valuation risk. So is this a discount or just a different kind of premium?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment split between valuation risk and potential upside, the best move is to review the underlying data yourself and move quickly if needed, then weigh what the market might be missing by digging into its 3 key rewards

Looking for more investment ideas?

If you are serious about sharpening your next move, do not stop at one stock. Line up several high conviction ideas so you are ready when prices shift.

• Target potential mispricing by scanning 46 high quality undervalued stocks that pair solid fundamentals with valuations that may not fully reflect their business performance.
• Strengthen your income stream by reviewing 10 dividend fortresses offering yields that stand out while still being tied to underlying business metrics.
• Prioritize resilience by checking 64 resilient stocks with low risk scores that score well on financial health and risk, so sudden shocks are less likely to catch you off guard.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com